750555
Last Update Posted: 2019-02-26
Recruiting has ended
All Genders accepted | 18 Years + |
4 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer
Phase II Study of Maintenance Tarceva (Erlotinib) in patients with locally advanced Head and Neck Cancer after treatment with curative intent
Eligibility
Relevant conditions:
Head and Neck Cancer
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov